107 related articles for article (PubMed ID: 10551774)
1. Transfection of an inducible p16/CDKN2A construct mediates reversible growth inhibition and G1 arrest in the AtT20 pituitary tumor cell line.
Frost SJ; Simpson DJ; Clayton RN; Farrell WE
Mol Endocrinol; 1999 Nov; 13(11):1801-10. PubMed ID: 10551774
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis of pituitary tumors.
Farrell WE; Clayton RN
Front Neuroendocrinol; 2000 Jul; 21(3):174-98. PubMed ID: 10882539
[TBL] [Abstract][Full Text] [Related]
3. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.
Kirsch M; Mörz M; Pinzer T; Schackert HK; Schackert G
Genes Chromosomes Cancer; 2009 Feb; 48(2):143-54. PubMed ID: 18973139
[TBL] [Abstract][Full Text] [Related]
4. Hypermethylation of the p16/CDKN2A/MTSI gene and loss of protein expression is associated with nonfunctional pituitary adenomas but not somatotrophinomas.
Simpson DJ; Bicknell JE; McNicol AM; Clayton RN; Farrell WE
Genes Chromosomes Cancer; 1999 Apr; 24(4):328-36. PubMed ID: 10092131
[TBL] [Abstract][Full Text] [Related]
5. CDKN2A/p16 inactivation is related to pituitary adenoma type and size.
Seemann N; Kuhn D; Wrocklage C; Keyvani K; Hackl W; Buchfelder M; Fahlbusch R; Paulus W
J Pathol; 2001 Apr; 193(4):491-7. PubMed ID: 11276008
[TBL] [Abstract][Full Text] [Related]
6. The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.
Dirks PB; Rutka JT; Hubbard SL; Mondal S; Hamel PA
Oncogene; 1998 Aug; 17(7):867-76. PubMed ID: 9780003
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of DNA methylation by 5-aza-2'-deoxycytidine suppresses the growth of human tumor cell lines.
Bender CM; Pao MM; Jones PA
Cancer Res; 1998 Jan; 58(1):95-101. PubMed ID: 9426064
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the p16 gene in human pituitary nonfunctioning tumors by hypermethylation is more common in null cell adenomas.
Ruebel KH; Jin L; Zhang S; Scheithauer BW; Lloyd RV
Endocr Pathol; 2001; 12(3):281-9. PubMed ID: 11740049
[TBL] [Abstract][Full Text] [Related]
10. Methylation mechanisms in pituitary tumorigenesis.
Farrell WE; Simpson DJ; Frost SJ; Clayton RN
Endocr Relat Cancer; 1999 Dec; 6(4):437-47. PubMed ID: 10730899
[TBL] [Abstract][Full Text] [Related]
11. Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc.
Haviernik P; Schmidt M; Hu X; Wolff L
Oncogene; 2003 Mar; 22(11):1600-10. PubMed ID: 12642863
[TBL] [Abstract][Full Text] [Related]
12. Staurosporine-induced apoptosis is independent of p16 and p21 and achieved via arrest at G2/M and at G1 in U251MG human glioma cell line.
Yamasaki F; Hama S; Yoshioka H; Kajiwara Y; Yahara K; Sugiyama K; Heike Y; Arita K; Kurisu K
Cancer Chemother Pharmacol; 2003 Apr; 51(4):271-83. PubMed ID: 12721754
[TBL] [Abstract][Full Text] [Related]
13. CDKN2A/p16 is inactivated in most melanoma cell lines.
Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
[TBL] [Abstract][Full Text] [Related]
14. Tumor suppressor gene p16/INK4A/CDKN2A-dependent regulation into and out of the cell cycle in a spontaneous canine model of breast cancer.
Agarwal P; Sandey M; DeInnocentes P; Bird RC
J Cell Biochem; 2013 Jun; 114(6):1355-63. PubMed ID: 23238983
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
16. The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients.
Takita J; Hayashi Y; Nakajima T; Adachi J; Tanaka T; Yamaguchi N; Ogawa Y; Hanada R; Yamamoto K; Yokota J
Oncogene; 1998 Dec; 17(24):3137-43. PubMed ID: 9872329
[TBL] [Abstract][Full Text] [Related]
17. RB status as a determinant of response to UCN-01 in non-small cell lung carcinoma.
Mack PC; Gandara DR; Bowen C; Edelman MJ; Paglieroni T; Schnier JB; Gelmann EP; Gumerlock PH
Clin Cancer Res; 1999 Sep; 5(9):2596-604. PubMed ID: 10499638
[TBL] [Abstract][Full Text] [Related]
18. Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells.
Dirks PB; Patel K; Hubbard SL; Ackerley C; Hamel PA; Rutka JT
Oncogene; 1997 Oct; 15(17):2037-48. PubMed ID: 9366521
[TBL] [Abstract][Full Text] [Related]
19. Small deletions but not methylation underlie CDKN2A/p16 loss of expression in conventional osteosarcoma.
Mohseny AB; Tieken C; van der Velden PA; Szuhai K; de Andrea C; Hogendoorn PC; Cleton-Jansen AM
Genes Chromosomes Cancer; 2010 Dec; 49(12):1095-103. PubMed ID: 20737480
[TBL] [Abstract][Full Text] [Related]
20. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy.
Stone S; Dayananth P; Kamb A
Cancer Res; 1996 Jul; 56(14):3199-202. PubMed ID: 8764106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
